1191 related articles for article (PubMed ID: 33279374)
1. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design.
Li X; Guo X; Fan X; Feng T; Wang C; Yao Z; Xu X; Chen Z; Wang H; Xie S; He J; Zhuo K; Xiang Q; Cen H; Wang J; Smith RC; Jin H; Keshavan MS; Marder SR; Davis JM; Jiang K; Xu Y; Liu D
Schizophr Res; 2021 Apr; 230():87-94. PubMed ID: 33279374
[TBL] [Abstract][Full Text] [Related]
2. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
3. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
4. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
5. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study.
Kahn RS; Winter van Rossum I; Leucht S; McGuire P; Lewis SW; Leboyer M; Arango C; Dazzan P; Drake R; Heres S; Díaz-Caneja CM; Rujescu D; Weiser M; Galderisi S; Glenthøj B; Eijkemans MJC; Fleischhacker WW; Kapur S; Sommer IE;
Lancet Psychiatry; 2018 Oct; 5(10):797-807. PubMed ID: 30115598
[TBL] [Abstract][Full Text] [Related]
6. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
7. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
[TBL] [Abstract][Full Text] [Related]
8. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
[TBL] [Abstract][Full Text] [Related]
9. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.
Stroup TS; McEvoy JP; Swartz MS; Byerly MJ; Glick ID; Canive JM; McGee MF; Simpson GM; Stevens MC; Lieberman JA
Schizophr Bull; 2003; 29(1):15-31. PubMed ID: 12908658
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
11. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics.
Leucht S; Winter-van Rossum I; Heres S; Arango C; Fleischhacker WW; Glenthøj B; Leboyer M; Leweke FM; Lewis S; McGuire P; Meyer-Lindenberg A; Rujescu D; Kapur S; Kahn RS; Sommer IE
Schizophr Bull; 2015 May; 41(3):549-58. PubMed ID: 25786408
[TBL] [Abstract][Full Text] [Related]
12. Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.
Barnes TR; Leeson VC; Paton C; Marston L; Davies L; Whittaker W; Osborn D; Kumar R; Keown P; Zafar R; Iqbal K; Singh V; Fridrich P; Fitzgerald Z; Bagalkote H; Haddad PM; Husni M; Amos T
Health Technol Assess; 2017 Sep; 21(49):1-56. PubMed ID: 28869006
[TBL] [Abstract][Full Text] [Related]
13. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
[TBL] [Abstract][Full Text] [Related]
14. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
Smith RC; Leucht S; Davis JM
Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
[TBL] [Abstract][Full Text] [Related]
16. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis.
Agid O; Arenovich T; Sajeev G; Zipursky RB; Kapur S; Foussias G; Remington G
J Clin Psychiatry; 2011 Nov; 72(11):1439-44. PubMed ID: 21457676
[TBL] [Abstract][Full Text] [Related]
17. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians.
Naber D; Lambert M
CNS Drugs; 2009 Aug; 23(8):649-59. PubMed ID: 19594194
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
19. Risperidone versus other atypical antipsychotic medication for schizophrenia.
Gilbody SM; Bagnall AM; Duggan L; Tuunainen A
Cochrane Database Syst Rev; 2000; (3):CD002306. PubMed ID: 10908551
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
